Aids
42-year HIV survivor tells CROI she has gone ‘from fear to courage’
SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed her experiences of living with HIV.
Q&A: Improving access to long-acting injectables for HIV prevention
A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables for HIV prevention which included the need for prior authorization and funding issues.
Disruptions in US funding could threaten HIV care for children in Africa
Millions of children in Africa rely on funding from the United States for HIV care or testing — support that was threatened last month when President Donald J. Trump froze foreign aid spending after taking office.
‘People are going to die’: US foreign aid pause hits life-saving HIV, malaria programs
A 90-day review of U.S. foreign aid spending ordered by President Donald J. Trump has halted global health programs, including the U.S. President’s Emergency Plan for AIDS Relief and the President’s Malaria Initiative.
No HIV vaccine on the horizon but research shows other tools, efforts are plentiful
Although there is still no HIV vaccine and no promising candidates in the pipeline, data published throughout 2024 show the significant impacts of prevention efforts and tools.
Does the world still need an HIV vaccine? Experts say yes
Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work.
Expected drop in HIV care providers may signal potential shift to primary care physicians
A notable proportion of health care providers plan to reduce or stop providing HIV care over the next half decade, even as the need for such care is expected to rise, results from a quantitative national survey showed.
Twice-yearly injections prevent HIV in another phase 3 trial
Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.
HHS announces more than $1.4B for HIV care for people with low incomes
HHS this week announced that it will allocate more than $1.4 billion in funding through the Ryan White HIV/AIDS Program to help people with HIV who have low incomes receive medication and care.
Study: Virally suppressed HIV does not increase mortality risk with pneumonia
People with virally suppressed HIV who are hospitalized with community acquired pneumonia do not have a higher mortality risk than people without HIV, according to a study.